Conatus pharmaceuticals inc. (CNAT)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Operating activities
Net loss

-3,481

-2,729

-3,253

-656

-4,747

-3,906

-4,589

-4,497

-5,018

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-3,623

-

-6,866

-6,471

-7,271

-6,044

-6,067

-6,057

-5,979

-5,336

-6,437

-5,303

-5,243

-5,125

-3,320

-4,873

-2,296

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

0

11

21

21

20

19

18

27

27

27

27

28

26

26

26

26

26

17

16

16

17

16

14

3

3

2

2

2

2

Stock-based compensation expense

936

914

1,152

1,161

926

897

948

929

983

1,049

986

813

1,250

897

745

808

901

741

842

910

821

764

692

494

379

156

75

4

21

Noncash other financing expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

-175

-2,895

-547

Amortization of premiums and discounts on marketable securities, net

0

-5

-37

-68

-94

-111

-103

-72

-55

-55

-23

3

7

-1

-21

5

22

44

78

101

102

-

-

-

-

-

-

-

-

Accrued interest included in convertible note payable

-

-

-

-

-

136

188

187

185

189

190

186

93

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquisition of in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Share-based compensation in lieu of salaries

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Noncash license expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Amortization of premium on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-105

-158

-195

-

-34

0

-8

Changes in operating assets and liabilities:
Collaboration receivables

-122

-1,528

-1,544

-666

183

-432

-744

-994

2,480

3,367

-7,000

7,000

-2,500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid and other current assets

-191

-475

449

-163

-453

-175

-28

62

-339

-335

322

127

9

-90

260

-880

-224

1,102

320

35

-272

0

156

-47

141

-68

455

74

7

Other assets

-

-

-

-

-

-

-

-

-

0

0

669

203

-

-

-

-

-

-

-

-

0

0

0

62

-

0

-25

25

Accounts payable and accrued expenses

-399

-1,950

-2,857

1,319

1,133

-2,897

-2,529

-3,012

2,678

1,021

2,355

2,894

368

2,953

355

-200

-252

173

-280

465

-939

-136

665

304

665

719

346

37

-697

Accrued compensation

13

-65

-480

-152

-1,295

254

491

390

-913

198

444

428

-1,413

742

370

349

-544

45

263

258

-278

-86

468

344

-857

944

-15

17

15

Deferred revenue

0

-404

-1,726

-7,596

-3,164

-3,732

-3,556

-3,921

-3,890

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lease liabilities, net

-36

-17

-15

-14

-13

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lease liabilities

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-3,009

-6,998

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

14

12

10

10

9

9

7

7

6

5

3

3

-73

-24

-32

-35

-

-

-

-

-

-

-

-

Net cash used in operating activities

-2,654

-1,982

-6,100

-5,156

-6,964

-9,038

-8,372

-9,293

-8,154

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Investing activities
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-8,009

-

-5,655

-4,604

-6,898

-6,848

-5,441

-4,307

-5,947

-4,624

-4,623

-3,950

-5,061

-3,078

-3,157

-1,964

-2,431

Maturities of marketable securities

0

4,372

11,970

9,500

19,000

13,250

19,510

18,050

18,875

24,620

28,948

19,315

8,994

13,750

6,500

10,472

13,875

17,850

21,070

9,076

14,578

7,418

17,450

16,173

13,031

-

-

-

-

Purchase of marketable securities

0

0

993

10,077

4,424

5,959

9,611

13,850

10,217

12,571

27,316

27,687

54,149

15,946

6,495

14,222

4,240

11,627

10,900

25,625

10,211

4,099

9,600

6,297

9,642

-

-

-

-

Maturities of investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

3,725

Purchase of investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Cash paid to acquire in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Capital expenditures

0

0

0

2

9

51

10

0

5

0

4

19

2

2

0

2

105

-

-

-

-

44

130

54

12

3

0

0

0

Net cash provided by investing activities

0

4,372

10,977

-579

14,567

7,240

9,889

4,200

8,653

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financing activities
Issuance of preferred stock for cash, net of offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Issuance of common stock related to initial public offering, net of offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from stock issuances related to exercise of stock options

-

-

-

-

-

-

-

-

37

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

12

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-45,157

-

4

-3,752

9,529

6,138

10,167

-16,552

4,366

3,273

7,719

9,821

3,375

-27,897

-24,223

0

3,725

Proceeds from issuance of convertible note payable, net

-

-

-

-

-

-

-

-

-

-

-

0

12,500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Principal payment on promissory note

-

-

-

-

-

-

-

-

-

0

0

0

1,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock, net

-

-

-

-

-

-

-

-

-

-

-

-

-

1,740

6,505

2,199

3,076

-

-

-

-

-

-

-

-

58,567

28

2

10

Issuance of promissory notes and warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,001

0

Distribution to wholly owned subsidiary in connection with spin-off of Idun Pharmaceuticals, Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

500

Deferred financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

66

30

-

-

-

-

-

-

-

-

Proceeds from stock issuances related to exercise of stock options and employee stock purchase plan

-

-

-

-

-

-

-

-

-

76

15

20

58

73

0

31

1

35

-0

46

2

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

55

152

117

37

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash and cash equivalents

-2,654

-

-

-

7,603

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

11,558

-

6,505

2,230

3,078

27

903

21,487

-28

-60

-168

40

12

-0

59,235

404

-489

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-4,976

536

-

-1,405

-710

-41,608

43,769

854

-6,126

5,709

-682

5,629

626

-1,609

-1,412

2,927

5,912

-1,673

-30,976

31,854

-1,559

804

Supplemental disclosure of cash flow information:
Cash paid for interest

-

-

-

-

-

-

-

-

-

0

0

0

5

17

17

17

17

17

17

17

17

17

17

17

17

17

53

0

17

Deferred public offering costs included in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

185

-

-

-

-

-

-

-

-

Conversion of notes payable for preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Conversion of notes payable for common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Issuance of warrants in conjunction with debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

119

506

0

Issuance of note payable related to acquisition of in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0